Radiotherapy can be avoided in patients with complete macroscopic resection and absence of residual tumor in post-operative images; they must be carefully followed using imaging techniques and, in the case of recurrence, they should be re-operated and/or irradiated.
Acromegaly is a rare, chronic endocrine disease, characterized by enhanced growth hormone (GH) secretion and elevated insulin-like growth factor-I (IGF-I) levels, the most frequent cause of which is a pituitary adenoma 1• Persistently elevated GH and IGF-I levels lead to substantial morbidity and mortality 2 • Control of GH and IGF-1 secretion is decisive in improving survival, 3 and optimum management of the disease requires a reduction in GH levels to <2.5 ng/mL and normalisation of IGF-1 levels 3• Somatostatin analogues (SSAs) have become the pillar of acromegaly medical therapy in patients unsuitable for, or refusing surgery, after failure of surgical treatment, or in selected cases as primary treatment 4• Initial recommended doses of the SSA Lanreotide Autogel are 60, 90 and 120 mg administered every 28 days.Experience in Spanish hospitals indicated that a longer dosage interval could be used in well controlled patients with similar efficacy. 5 Starting dose for Lanreotide Autogel prescribed in clinical practice may differ from prescribing recommendations
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.